Kymera Therapeutics - 1792 Exchange

Rating Overview

Kymera Therapeutics is Lower Risk.

Kymera Therapeutics is Lower Risk. The company does not yield to political activism in shaping corporate governance, preventing initiatives that potentially alienate consumers, divide employees, and harm shareholders. The company implements race and identity-based policies that replace merit, excellence, and integrity with preferential treatment and outcomes. Overall, the company does not embrace corporate initiatives that redirect its central focus from business goals to partisan policies and divisive issues. This approach protects free exercise, free speech, and free enterprise.

Rating Criteria

Corporate Weaponization Risk Levels
Criteria	Risk Level
Cancellations	Lower Risk
Discriminatory Philanthropy	Lower Risk
Employment Protection	High Risk

Corporate Weaponization ⓘ

Corporate Governance and Public Policy Risk Levels
Criteria	Risk Level
Advocacy Bias	Medium Risk
Funding	Lower Risk
Political Actions	No Data

Corporate Governance and Public Policy ⓘ

Rating Criteria Detail

Criteria Risk Level Rationale

Corporate Weaponization

Criteria:

Has canceled customers, suppliers, or vendors due to their political views or religious beliefs OR corporately boycotts, divests, or sanctions regions, people groups, or industries.

Risk Level:

Lower

Rationale:

Kymera Therapeutics has not publicly canceled customers, suppliers, or vendors based on political views or religious beliefs (1).

Criteria:

Charitable giving (including employee matching programs) policies or practices discriminate against charitable organizations based on views or religious beliefs.

Risk Level:

Lower

Rationale:

Kymera Therapeutics does not appear to discriminate against charitable organizations based on views or beliefs (1).

Criteria:

Employment policies fail to protect against viewpoint or other discrimination and/or are ideological in nature.

Risk Level:

High

Rationale:

Kymera Therapeutics appears to prioritize diversity over merit in its leadership composition. From its Nominating and Corporate Governance Guidelines: “In evaluating director candidates, including directors eligible for re-election, the Nominating Committee will consider the following… Such factors as character, integrity, judgment, diversity, independence, skills, education, expertise, business acumen, business experience, length of service, understanding of the Company’s business and industry, conflicts of interest, and other commitments” (1). It does not provide viewpoint protections for its employees (2).

Corporate Governance and Public Policy

Criteria:

Uses corporate reputation to support causes, organizations, or policies hostile to freedom of expression.

Risk Level:

Medium

Rationale:

Kymera Therapeutics’ CEO Nello Mainolfi signed MassBio’s Open Letter 2.0, committing the company to implement DEI across various facets of corporate governance including its recruitment, hiring, supply chain, executive compensation, external partnerships, and company programming. Furthermore, signatories are expected to use their influence to promote DEI throughout the company, encourage employees to “self-educate on racism and to contribute to the race dialogue”, and ensure transparency and accuracy of reporting on instances of microaggressions in the workplace while holding leaders accountable for their responses (1)(2). Kymera Therapeutics has not supported ideological causes or policies (3).

Criteria:

Uses corporate funds to advance ideological causes, organizations, or policies hostile to freedom of expression.

Risk Level:

Lower

Rationale:

Kymera Therapeutics has not used corporate funds to advance ideological causes, organizations, or policies (1).

Criteria:

Uses corporate political actions and/or financial contributions for ideological, non-business purposes.

Risk Level:

N/A

Rationale:

Kymera Therapeutics does not operate a PAC or engage in lobbying at this time (1)(2)(3).